Thomas Ortel is a Hematology physician affiliated with Duke University. OpenAlex indexes 475 publications with 29,251 citations (h-index 77); ClinicalTrials.gov lists 13 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
Sponsor: Duke University
- Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
Sponsor: Carelon Research
- "Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
Sponsor: Duke University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
3 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
93.8%Factor Xa inhibitor55.9%Eliquis73%Xarelto24%Fondaparinux Sodium4%Part D<11 patientsVitamin K antagonist30.6%Warfarin Sodium61%Jantoven39%Part D≥37 patients+ 1 more class in this area
Cancer & immunology
3.9%Antimetabolite2.1%Droxia100%Part D<11 patientsKinase inhibitor1.8%Sirolimus100%Part D<11 patientsNervous system
2.3%Opioid Agonist2.3%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
12 NIH research awards on record, funded 1997–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - The 2023 <scp>ACR</scp>/<scp>EULAR</scp> Antiphospholipid Syndrome Classification Criteria
Arthritis & Rheumatology
2023 - 2023 ACR/EULAR antiphospholipid syndrome classification criteria
Annals of the Rheumatic Diseases
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
Jonathan Piccini, MD
Duke University
Vance Fowler, MD
Duke University
Joseph Antin, MD
Boston University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”